Compare a single combo pill of dapagliflozin, pioglitazone, and metformin with taking the three drugs separately in fasting adults
Official title: An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of "BR3006" and Co-administration of "BR3006A", "BR3006B" and "BR3006C" in Healthy Adult Volunteers
Run by Boryung Pharmaceutical Co., Ltd · NCT07083388 · Data updated 2026-11-12
This will test whether a single combination tablet of dapagliflozin 10 mg, pioglitazone 30 mg, and metformin 1000 mg gives similar drug levels and is as safe as taking the three medicines separately in healthy adults when fasting.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 52 (estimated) |
| Sponsor | Boryung Pharmaceutical Co., Ltd Industry-sponsored |
| Locations | 1 site (Seoul, Gwanak-gu) |
| Status | Recruiting |
| Started | July 3, 2025 |
| Main results expected | July 3, 2026 |
| Study ends | July 3, 2026 |
| Registry record updated | July 24, 2025 |
| Trial ID | NCT07083388 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults aged 19 years or older who meet laboratory and ECG screening criteria and can give informed written consent are the intended participants.
✕Probably not a fit
People who recently received another investigational product, have had gastrointestinal surgery, or have active gastrointestinal disease (and therefore are ineligible) would not benefit from participating in this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This open-label, randomized, single-dose, two-sequence, two-period crossover Phase 1 study will enroll 52 healthy adult volunteers to compare the pharmacokinetics and safety of a fixed-dose combination tablet versus co-administration of the three separate tablets while fasting. Each participant receives both treatments in separate periods to allow within-subject comparison of blood drug concentrations and adverse events. Safety monitoring includes laboratory tests, ECGs, and recording of adverse events. The primary focus is demonstrating comparable pharmacokinetic profiles between the combination tablet and the separate products, with safety and tolerability as secondary measures.
Why it matters
Potential benefit: If successful, a single fixed-dose tablet could simplify dosing and improve convenience and adherence for people who take these three diabetes medicines.
How similar studies have gone: Fixed-dose combination versus co-administration pharmacokinetic and safety studies for diabetes drugs are common and have frequently shown comparable pharmacokinetics, so this approach is established rather than novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged over 19 at the time of consent * Those who are eligible to participate in the clinical trial at the discretion of the principal investigator (or a subinvestigator) through laboratory tests such as hematology tests, blood chemistry tests, serology tests, urine tests, and electrocardiogram (ECG) tests that were planned/performed with specification to the investigational product. * Those who provided written consent after receiving sufficient explanations and fully understood the objective and details of this clinical trial, the characteristics of the investigational product, and the expected adverse events. Exclusion Criteria: * Those who have administered investigational products within 6 months from the first dose administration date in another clinical trial (including bioequivalent studies) (The end of study date is based on the last dose administration date.) * Those who have undergone gastrointestinal surgeries or have gastrointestinal diseases (except appendectomy or hernia surgery) that may affect the absorption of the investigational products * Those who are pregnant, suspected of pregnancy, or nursing
Where it's running
-
H Plus Yangji Hospital
Seoul, Gwanak-gu, South Korea Recruiting
Study contacts
- Study coordinator: Shinyoung Oh
- Email: syoh@boryung.co.kr
- Phone: +82 2-708-8000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing
A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.
-
DiaFootCare: a mobile app to help adults with diabetic foot ulcers manage self-care in Oman
A mobile app called DiaFootCare will be tested to see if it helps adults with diabetic foot ulcers in Oman take better care of themselves and improve healing compared with usual care.
-
Predictive CGM with App for people with type 1 or insulin-treated type 2 diabetes
This study tests whether using the Accu-Chek SmartGuide CGM with its Predict App can reduce fear of hypoglycemia and improve related behaviors and confidence in adults with type 1 or insulin-treated type 2 diabetes.
-
SugarVita 2.0: a 12-week digital game for adults with type 2 diabetes
This 12-week pilot tests SugarVita 2.0, a serious digital game, to see if it helps adults with type 2 diabetes manage their condition and feel more confident.
-
Linking social care with healthcare to help manage chronic diseases
This trial tests whether pairing patients with trained community health workers can help them get transportation, healthy food, information, and better access to care to improve health in conditions like hypertension, diabetes, and high cholesterol.
-
Transcutaneous and topical photobiomodulation for diabetic foot ulcers
This phase 2 trial tests whether combining transcutaneous and topical photobiomodulation helps heal foot ulcers in adults with diabetes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.